AMENDMENTS TO THE CLAIMS

Please **amend** the claims as follows:

1. (Original) A method of neuroprotection which comprises administering a compound to a subject who is experiencing or has experienced a stroke, or other interruption of cerebral blood flow by other etiologies, the compound being an AMPK inhibitor.

2. (Original) The method of claim 1, wherein the compound is not a peptide or other biological or biologically-derived material.

3. (Original) The method of claim 2, wherein the compound is C75.

4. (Original) The method of claim 2, wherein the compound is Compound C.

5. (Original) The method of claim 2, wherein the compound is not C75 or Compound C.

6. (Original) The method of claim 1, wherein the compound is a small molecule.

7.-9. (Cancelled)

10. (New) The method of claim 1, wherein said compound reduces pAMPK level.

11. (New) The method of claim 1, wherein said compound is a direct inhibitor of AMPK.

12. (New) The method of claim 1, wherein said compound is an indirect inhibitor of AMPK.

13. (New) The method of claim 1, wherein said compound is a CPT-1 stimulator.

14. (New) A method of neuroprotection which consists of administering a compound to a subject who is experiencing or has experienced a stroke, or other interruption of cerebral blood flow by other etiologies, the compound being an AMPK inhibitor.

15. (New) The method of claim 14, wherein the compound is not a peptide or other biological or biologically-derived material.

16. (New) The method of claim 14, wherein the compound is C75.

17. (New) The method of claim 14, wherein the compound is Compound C.

18. (New) The method of claim 14, wherein the compound is not C75 or Compound C.

19. (New) The method of claim 14, wherein the compound is a small molecule.

20. (New) The method of claim 14, wherein said compound reduces pAMPK level.

21. (New) The method of claim 14, wherein said compound is a direct inhibitor of AMPK.

22. (New) The method of claim 14, wherein said compound is an indirect inhibitor of AMPK.

23. (New) The method of claim 14, wherein said compound is a CPT-1 stimulator.